HuTARG™, a New Tool for the Next Generation of First-in-class Biologics
The traditional antibody generation technologies including hybridomas from transgenic animals, phage and yeast display have been in use for over a decade. These core technologies have generated many exciting medicines for patients. However, it is clear that certain important target classes are not easily accessible to these older technologies. GPCRs, ion channels, agonist antibodies, antibodies to MHC/peptide complexes offer unique First-in-Class opportunities and I believe need a new paradigm of tools to solve these traditional challenges.
Innovative Targeting Solutions has created the first truly new protein engineering technology in decades. The HuTARG™ platform introduces the novel strategy of De Novo Engineering™ that allows for repertoires of billions to be generated in a mammalian cell; it is the only technology that can achieve this level of diversity in vitro within a mammalian cell and for the first time makes mammalian display a viable approach for drug discovery. At the heart of this new paradigm of protein engineering is V(D)J recombination, nature’s most powerful diversity generation system, which allows the cell to generate in situ diversity without the transformation of recombinant libraries. This approach opens up the ability to interrogate full length functional receptors including multi-spanning receptors such as GPCRs and ion channels in their native conformations. And more importantly, it allows for these receptors to be evaluated functionally. The technology can be applied to antibody generation or affinity maturation where billions of antibodies can be interrogated at the single cell level by FACS for any criteria that can be programmed into a mammalian cell (affinity, specificity, agonism, antagonism).
The Company’s HuTARG™ platform does not represent an incremental advance but a fundamental change towards engineering biologics and discovering first in class biologics.
Innovative Targeting Solutions Inc.